Vascular Solutions, Inc. : Vascular Solutions Announces Q4 Earnings Date

For Release: Tuesday, January 15, 2013, 3:05 pm Central Time NEWS RELEASE Contact: James Hennen, CFO Phillip Nalbone, VP Corp. Dev. Vascular Solutions, Inc.

[phone]

VASCULAR SOLUTIONS ANNOUNCES Q4 EARNINGS DATE

MINNEAPOLIS, Minnesota - Vascular Solutions, Inc. (Nasdaq: VASC) today announced that it will host a live Webcast of its fourth quarter conference call on Tuesday, February 5th at 3:30pm CST. Vascular Solutions' Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company's fourth quarter results. The company will issue an earnings news release after market close on Tuesday, February
5th.
To access the Webcast, go to the investor relations portion of the company's website, http://www.vasc.com, on the day of the conference call and click on the conference call link.
The Webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of approximately 70 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists,
interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward- looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2012 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vasc.com.
# # #